Saleh Raed Obaid, Hjazi Ahmed, Rab Safia Obaidur, Uthirapathy Subasini, Ganesan Subbulakshmi, Shankhyan Aman, Ravi Kumar M, Sharma Girish Chandra, Kariem Muthena, Ahmed Jawad Kadhim
Medical Laboratory Techniques Department, College of Health and medical technology, University of Al Maarif, Anbar, Iraq.
Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
J Biochem Mol Toxicol. 2025 Apr;39(4):e70218. doi: 10.1002/jbt.70218.
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations and impaired apoptosis, all of which lead to excessive proliferation of malignant blood cells in the bone marrow. It is these mutations that cause tumor heterogeneity, which is linked to a higher risk of relapse and death and makes anti-AML treatments like HSCT, chemotherapy, and immunotherapy (ICI, CAR T-cell-based therapies, and cancer vaccines) less effective. Single-cell RNA sequencing (scRNA-seq) also makes it possible to find cellular subclones and profile tumors, which opens up new diagnostic and therapeutic targets for better AML management. The HSCT process works better when genetic and transcriptional information about the patient and donor stem cells is collected. This saves time and lowers the risk of harmful side effects happening in the body.
急性髓系白血病（AML）是由髓系母细胞成熟和分化改变、转录/表观遗传改变以及凋亡受损引起的，所有这些都会导致骨髓中恶性血细胞过度增殖。正是这些突变导致了肿瘤异质性，这与更高的复发和死亡风险相关，并且使得异基因造血干细胞移植（HSCT）、化疗和免疫疗法（免疫检查点抑制剂、基于嵌合抗原受体T细胞的疗法和癌症疫苗）等抗AML治疗效果较差。单细胞RNA测序（scRNA-seq）也使得发现细胞亚克隆和描绘肿瘤成为可能，这为更好地管理AML开辟了新的诊断和治疗靶点。当收集到患者和供体干细胞的基因和转录信息时，HSCT过程会更顺利。这节省了时间，并降低了体内出现有害副作用的风险。
